KB105

Phase 1/2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

TGM-1 Related Autosomal Recessive Congenital Ichthyosis

Conditions

TGM-1 Related Autosomal Recessive Congenital Ichthyosis

Trial Timeline

Aug 27, 2019 → Mar 1, 2025

NCT ID

NCT04047732

About KB105

KB105 is a phase 1/2 stage product being developed by Krystal Biotech for TGM-1 Related Autosomal Recessive Congenital Ichthyosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04047732. Target conditions include TGM-1 Related Autosomal Recessive Congenital Ichthyosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05735158	Phase 2	UNKNOWN	Mar 1, 2023	Apr 1, 2024	Autosomal Recessive Ichthyosis
NCT04047732	Phase 1/2	UNKNOWN	Aug 27, 2019	Mar 1, 2025	TGM-1 Related Autosomal Recessive Congenital Ichthyosis